American Society of Interventional Pain Physicians | March 28, 2018
20 th Annual ASIPP Meeting A Success

The 20th Anniversary meeting was in collaboration with the Florida Society of Interventional Pain Physicians and in Orlando, Florida on Thursday, March 15 through Saturday, March 17, 2018, at Marriott Orlando World Center. Nearly 975 people attended the meeting with a record number of vendors filling the exhibition hall.
Click HERE for Photo Gallery.

Please make plans to join us for next year’s meeting May 3-5, 2019 at Caesar’s Palace in Las Vegas.
Essentials of Interventional Techniques in Managing Chronic Pain
Available for Order!
  • Comprehensive textbook of interventional techniques in managing chronic pain

  • Covers spinal interventional techniques, peripheral nerve blocks, sympathetic interventional techniques, soft tissue and joint injections and implantables

  • Step-by-step guidance backed up by the latest evidence

This comprehensive review covers the full and latest array of interventional techniques for managing chronic pain. Chapters are grouped by specific treatment modalities that include spinal interventional techniques, nonspinal and peripheral nerve blocks, sympathetic interventional techniques, soft tissue and joint injections, and implantables. Practical step-by-step and evidence-based guidance is given to each approach in order to improve the clinician's understanding. Innovative and timely, Essentials of Interventional Techniques in Managing Chronic Pain is a critical resource for anesthesiologists, neurologists, and rehabilitation and pain physicians.
Click HERE to order
Graphic: Opioid Painkiller Is Top Prescription In 10 States
Americans fill about  4.5 billion prescriptions  each year, at a cost of more than  $323 billion . But what are we actually buying? In 10 states, the top prescriptions are opioid pain pills that are mixtures of acetaminophen and hydrocodone (brand names Vicodin and Norco), according to new data from GoodRx , an online prescription cost service.
The company looked at the top 10 drugs prescribed in each state from March 2017 to February 2018 and then presented the data as a map.
Registration Now Open!

ASIPP NIPM-QCDR Webinar – April 11

Understand and adjust your performance to improve patient outcomes
Join the NIPM-QCDR team for a webinar outlining key enhancements to ASIPP's NIPM-QCDR for 2018. The presenters will share how the registry is bringing even more utility to interventional pain management to help you and your patients confidentially and securely report real-world patient outcomes following procedures performed in an office, surgery center, or hospital. You will receive a preview of new features and reports coming to the registry - including patient-reported outcomes - that will help you understand and adjust your performance to improve patient outcomes. Plus, learn about how the NIPM-QCDR can help you easily and satisfactorily meet CMS requirements and optimize reimbursements this year.
April 11 | 2pm ET
Presenters :
Spencer Heaton, M.D., M.B.A.
Lukasz Paszek, M.B.A.

Deploy Tech to Fight Opioid Crisis, Experts Tell Senators
WASHINGTON -- Interoperability, predictive analytics, e-prescribing: these were some of the terms buzzing around the dais at a hearing of the Senate Health, Education, Labor and Pensions Committee on Tuesday.
The focus of the hearing was to solicit expert input on the role of technology and data in addressing the opioid crisis. The committee is currently drafting legislation related to the epidemic, which it plans to mark-up as soon as late March.
Specifically, Chairman Lamar Alexander (R-Tenn.) asked the experts how the federal government can use the data it collects to identify and stop the overprescribing of opioids.
Chronic opioid users have 33% relative increase in likelihood of repeat spinal fusion within 1 year — 8 takeaways
Researchers from The Ohio State University Wexner Medical Center in Columbus investigated the impact of chronic opioid therapy on complications following spinal fusion surgery.
The study included 24,610 lumbar spinal fusion patients; 5,550 of the patients were taking opioids for more than six months before their surgery. Some factors associated with an increased rate of chronic opioid therapy include tobacco use disorder, drug abuse/dependence, anxiety, depression and inflammatory arthritis.
Spine published the study.
Click HERE to view February issue of IPM Reports

Interventional Pain Management Reports is an Open Access online journal, a peer-reviews journal dedicated to the publication of case reports, brief commentaries and reviews and letters to the editor. It is a peer-reviewed journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. 

Interventional Pain Management Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician . Interventional Pain Management Reports Interventional Pain Management Reports is an open access journal, available online with free full manuscripts.  

The benefits of publishing in an open access journal that has a corresponding
print edition journal are:  
  • Your article will have the potential to obtain more citations.
  • Your article will be peer-reviewed and published faster than other journals.
  • Your article can be read by a potentially much larger audience compared with traditional subscription-only journals.  
  • Open Access journals are FREE to view, download and to print.

So submit today your:
  • Case Reports
  • Technical Reports
  • Editorials
  • Short Perspectives

Click HERE to submit
U.S. Sen. Ron Johnson (R-Wis.), chairman of the Senate Homeland Security and Governmental Affairs Committee, released a  report  Wednesday, “Drugs for Dollars: How Medicaid Helps Fuel the Opioid Epidemic,” detailing cases involving Medicaid fraud and how the Medicaid program has contributed to the opioid crisis. Johnson also sent a letter and provided a copy of the report to Health and Human Services Acting Secretary Eric Hargan and Centers for Medicare and Medicaid Services Administrator Seema Verma. Chairman Johnson asked HHS and CMS to explain in detail what the Administration is doing to prevent Medicaid fraud relating to obtaining and selling opioids.
Report Report addresses Connection Between Opioid Manufacturers and Advocacy Groups

This report provides the first comprehensive snapshot of the financial connections between opioid manufacturers and advocacy groups and professional societies operating in the area of opioids policy. Drawing on disclosures from Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Mylan N.V., Depomed, Inc., and Insys Therapeutics, Inc., in response to requests from Ranking Member McCaskill, the sections below describe nearly $9 million in payments from these manufacturers to 14 outside groups working on chronic pain and other opioid-related issues between 2012 and 2017. In addition, physicians affiliated with these groups accepted more than $1.6 million in payments from the five manufacturers between 2013 and the present. In total, the five manufacturers have made more than $10 million in payments to these groups and affiliated individuals since January 2012.
Opioids vs Nonopioid Medications for Chronic Back, Knee, and Hip Osteoarthritis Pain

Opioids and nonopioid analgesics were found to provide similar improvements in pain-related function over a 1-year period in patients with chronic back pain or knee or hip osteoarthritis pain, according to a study published in the  Journal of the American Medical Association .
For this randomized trial ( identifier:  NCT01583985 ), a total of 240 patients with chronic back pain or knee or hip osteoarthritis pain were recruited from Veterans Affairs primary care clinics.

March/April 2018 Issue Features
Systematic Reviews
  • Discography in Chronic Spinal Pain
  • Neuropathic Pain in Acute and Subacute Neuropathies
  • Vitamin D Supplementation for Low Back Pain
Comprehensive Review
  • Chronic Pelvic Pain: A Review
Randomized Trials
  • Fluoroscopic Guided Radiofrequency of Genicular Nerves
  • Effects of a Sustained Release Formulation of Sodium Nitrite on Patients with Diabetic Neuropathy
  • Pulsed Radiofrequency in an Animal Model of Neuropathic Pain
  • Pulsed Radiofrequency Treatment for Chronic Post-Surgical Orchialgia

Click view full article pdfs available only online at: 
Conventional vs High-Frequency Spinal Cord Stimulation for Chronic Pain
In a preliminary study published in  Neuromodulation , high-frequency spinal cord stimulation was found to be more effective in treating chronic pain than conventional stimulation.
Although  spinal cord stimulation  (SCS) effectively alleviates chronic axial back pain in 50% to 70% of cases, it is accompanied by adverse effects (eg, frequent paresthesias). In the current pilot study, investigators sought to examine whether these issues could be resolved by alternating conventional stimulation (≤100 Hz) with high-frequency or "shuffle" stimulation (10,000 Hz).

District Court Orders Florida Company to Stop Distributing Adulterated and Misbranded Drugs
A federal court permanently enjoined a Deltona, Florida, company from selling and distributing unapproved and misbranded new drugs, the Justice Department announced today.
In a complaint filed March 14 at the request of the U.S. Food and Drug Administration (FDA), the United States alleged that MyNicNaxs LLC, Chevonne Torres, and Michael Banner sold sexual-enhancement and weight-loss products in violation of the Federal Food, Drug, and Cosmetic Act (FDCA). The complaint alleged that the defendants marketed products as drugs that could help treat or prevent a host of serious conditions or diseases. According to the complaint, the defendants made such claims without FDA approval and without proof of safety and efficacy.

The complaint further alleged that FDA tests showed some of the defendants’ products contained undisclosed pharmaceutical ingredients such as sildenafil, the active pharmaceutical ingredient in Viagra; sibutramine, the active pharmaceutical ingredient in a drug that was withdrawn from the market after clinical data indicated that it posed an increased risk of heart attack and stroke; and phenolphthalein, an ingredient that FDA deemed “not generally recognized as safe and effective” after studies indicated that it was a potential carcinogenic risk. The defendants agreed to be bound by a consent decree of permanent injunction filed in U.S. District Court for the Middle District of Florida.

Alere to Pay U.S. $33.2 Million to Settle False Claims Act Allegations Relating to Unreliable Diagnostic Testing Devices
Massachusetts-based medical device manufacturer Alere Inc. and its subsidiary Alere San Diego (Alere) have agreed to pay the United States $33.2 million to resolve allegations that Alere caused hospitals to submit false claims to Medicare, Medicaid, and other federal healthcare programs by knowingly selling materially unreliable point-of-care diagnostic testing devices, the Justice Department announced today.
“The United States is fortunate that innovative healthcare companies regularly develop medical devices that improve patients’ lives, often in remarkable ways,” said Acting Assistant Attorney General Chad A. Readler for the Justice Department’s Civil Division. “But the Department will hold medical device manufacturers accountable if they knowingly sell defective products that waste taxpayer dollars and adversely impact patient care.”  

The United States alleged that between January 2006 and March 2012, Alere knowingly sold materially unreliable rapid point-of-care testing devices marketed under the trade name Triage®. The Triage® devices aided in the diagnosis of acute coronary syndromes, heart failure, drug overdose, and other serious conditions, and the devices were frequently used in emergency departments where timely decisions are critical to ensuring proper patient care. According to the government’s allegations, Alere received customer complaints that put it on notice that certain devices it sold produced erroneous results that had the potential to create false positives and false negatives that adversely affected clinical decision-making. Nonetheless, the company failed to take appropriate corrective actions until FDA inspections prompted a nationwide product recall in 2012. Of the $33.2 million to be paid by Alere, $28,378,893 will be returned to the federal government and a total of $4,860,779 will be returned to individual states, which jointly funded claims for Triage devices submitted to state Medicaid programs.       

State Society News 
June 9-10, 2018
Midwest Societies of Interventional Pain Management Meeting
State Societies from Illinois, Indiana, Kentucky, Michigan, Missouri, Wisconsin, and Iowa .
Westin Michigan Avenue Chicago

April 18-22, 2018
GSIPP 2018 Annual Meeting
Georgia Society of Interventional Pain Physicians
The Ritz Carlton Reynolds, Lake Oconee

July 19-22, 2018
FSIPP 2018 Annual Meeting, Conference, and Trade Show
Florida Society of Interventional Pain Physicians
One South County Road, Palm Beach, FL 33480

Send in your state society meeting news to Holly Long,
ASIPP | Pain Physician Journal | Phone | Fax | Email